Healthcare SPAC Amanat Acquisition files for a $75 million IPO
IPO Overview
Amanat Acquisition, a blank check company targeting biotech and life sciences, filed on Friday with the SEC to raise up to $75 million in an initial public offering.
The company plans to raise $75 million by offering 7.5 million shares at $10. The offering does not contain warrants or rights.
Amanat Acquisition is led Chairman Sandeep Kulkarni, an experienced biotech executive who currently serves as CEO of Zura Bio, and CEO and Director Pavan Cheruvu, who previously served as CEO of Bitterroot Bio and Sio Gene Therapies. The SPAC plans to target the healthcare industry, particularly the biotechnology and life science sectors.
The Westfield, NJ-based company was founded in 2026. It plans to list on the Nasdaq under the symbol AMAN. Amanat Acquisition filed confidentially on March 18, 2026. Leerink Partners is the sole bookrunner on the deal.
About the Company
We are a blank check company. While we may pursue a business combination target in any business or industry, we intend to focus on healthcare or healthcare-related industries, which can benefit from the expertise and capabilities of our management team in order to create long-term shareholder value. Our sponsor, Amanat Sponsor Holdings LLC, is a Delaware limited liability company which was formed to invest in us. Although our sponsor is permitted to undertake any activities permitted under the Delaware Limited Liability Company Act and other applicable law, our sponsor’s business is focused on investing in us and directly or indirectly providing administrative services to members of our management team. As of the date of this prospectus, our Chairman of the Board, Dr. Sandeep Kulkarni is the sole member of our sponsor.